연구동향 분석

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

김연주 지원준 이재철 천성민 최창민 2022년

논문상세정보
인용/피인용
' Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Liquid biopsies
  • Osimertinib
  • T790M
  • nonsmallcelllungcarcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
48 0

0.0%

' Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion' 의 참고문헌

  • Screening for epidermal growth factor receptor mutations in lung cancer
    Rosell R [2009]
  • Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
    Kawamura T [2016]
  • Re-biopsy status among non-small cell lung cancer patients in Japan : a retrospective study
    Nosaki K [2016]
  • Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer
    Sacher AG [2016]
  • Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer
    Jenkins S [2017]
  • Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
    Mok TS [2017]
  • Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
    Soria JC [2018]
  • Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer : AURA study phase II extension component
    Yang JC [2017]
  • Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples
    Kiura K [2018]
  • Optimal DNA isolation method for detection of bacteria in clinical specimens by broad-range PCR
  • Non-small cell lung cancer : current treatment and future advances
    Zappa C [2016]
  • List of reimbursable drugs
  • Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients : a comparison between cell-free DNA and extracellular vesicle-derived DNA
    Lee JS [2018]
  • Liquid biopsy in lung cancer : present and future
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS [2009]
  • Feasibility of bronchial washing fluid-based approach to early-stage lung cancer diagnosis
    Ryu JS [2019]
  • Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer : a prospective multicenter study in a real-world setting(GFPC study 12-01)
    Chouaid C [2014]
  • FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations
  • Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naive non-small cell lung cancer patients
    Hur JY [2019]
  • Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial : Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer
  • Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity
    Han HS [2012]
  • Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer
    Lee SH [2020]
  • Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer : a meta-analysis
    Qiu M [2015]
  • Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC : French subset analysis of the ASSESS study
    Denis MG [2019]
  • Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor
    Helman E [2018]
  • Bronchoalveolar lavage in malignancy
    Poletti V [2007]
  • Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer
    Oxnard GR [2016]
  • Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid
    Park S [2017]
  • Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib(CO-1686)
    Karlovich C [2016]
  • AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
    Janne PA [2015]
  • A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
    박철규 [2019]